Amwell Reports Mixed Q4 Results, Shares Gain on Narrower-Than-Expected Loss
American Well Corp. (NYSE:AMWL), known as Amwell, released its financial results for the fourth quarter and full year ended December 31, 2025, after the market closed on Wednesday. The telehealth platform provider delivered a quarterly performance that notably exceeded analyst expectations on the bottom line, a development that appears to be driving a positive after-hours market reaction.
Fourth Quarter Earnings Snapshot
The core of the market's focus was on the company's performance relative to Wall Street's forecasts. Amwell reported a non-GAAP loss per share of $1.43 for the fourth quarter of 2025. This figure was significantly better than the consensus estimate, which anticipated a loss of $1.81 per share. On the top line, the company also surpassed expectations.
- Reported Revenue: $55.31 million
- Estimated Revenue: $53.75 million
- Reported Non-GAAP EPS: -$1.43
- Estimated Non-GAAP EPS: -$1.81
The dual beat on both revenue and earnings per share represents a clear positive for the quarter. The narrower loss is particularly noteworthy for a growth-oriented company in the competitive digital health sector, where investor patience for sustained losses has waned in recent years.
Market Reaction and Recent Performance
The immediate market response to the earnings report was favorable. In after-hours trading following the announcement, shares of Amwell rose approximately 6.2%. This uptick suggests investors are interpreting the better-than-expected loss containment as a constructive sign.
This positive after-hours move stands in contrast to the stock's performance over recent weeks. Prior to the earnings release, the stock had been under pressure.
- Over the past month, shares declined roughly 8.5%.
- In the two weeks leading up to the report, the stock was down about 6.9%.
The post-earnings bounce indicates the results may have alleviated some of the recent negative sentiment, at least in the short term.
Looking Ahead: Analyst Estimates for 2026
While the fourth-quarter results provided a boost, investor attention will quickly shift to the company's future trajectory. Management's commentary on the accompanying conference call regarding its outlook for 2026 will be scrutinized. Currently, Wall Street analysts have established estimates for the coming year that reflect expectations of continued challenges.
For the full year 2026, the consensus among analysts points toward ongoing losses, though the estimates provide a benchmark against which any company-provided guidance will be measured.
- Estimated FY 2026 Non-GAAP EPS: -$4.75
- Estimated FY 2026 Revenue: $245.22 million
For the immediate next quarter (Q1 2026), analysts are forecasting:
- Estimated Q1 2026 Non-GAAP EPS: -$1.35
- Estimated Q1 2026 Revenue: $58.98 million
Press Release Summary
The company's press release announced the availability of its full financial results for the quarter and year. Amwell emphasized its position as a provider of a comprehensive SaaS-based software platform for technology-enabled healthcare. The release noted that the company would host a conference call to discuss the results and provided details for accessing the webcast and a subsequent replay. Beyond the financial figures, the release highlighted the scale and scope of the Amwell platform, which is designed to offer payers and health systems a unified solution for a wide range of digital health needs, from urgent care to chronic condition management.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
